DAF
0.02
100%
ATC
0.001
-50%
FAU
0.009
50%
ARV
0.003
-25%
DXN
0.4
45.5%
RWL
0.15
-21.1%
ACU
0.14
33.3%
CHM
0.016
-20%
C7A
0.004
33.3%
ERE
0.012
-20%
M2M
0.008
33.3%
SP3
0.009
-18.2%
NXL
1.835
28.8%
KGN
3.705
-17.8%
AEU
0.565
22.8%
CDE
0.005
-16.7%
AUQ
0.045
21.6%
ENL
0.005
-16.7%
RRE
0.11
20.9%
RLG
0.005
-16.7%
COY
0.006
20%
AQX
0.006
-14.3%
RGL
0.012
20%
CRR
0.006
-14.3%
WRX
0.024
20%
RFT
0.006
-14.3%
M4M
0.007
16.7%
UNT
0.006
-14.3%
WSR
0.007
16.7%
LML
0.007
-12.5%
LOT
0.277
15.4%
EPI
0.405
-12%
EUR
0.352
15.4%
KRR
0.075
-11.8%
LEX
0.15
15.4%
G6M
3.3
-11.5%
CMP
0.27
14.9%
DTZ
0.023
-11.5%
AXN
0.031
14.8%
SNS
0.032
-11.1%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CRSP U.S. FDA approved first therapy utilising CRISPR

The beginning of a new era in medicine: The U.S. FDA has today approved cell-based gene therapy Casgevy, marking the first FDA-approved therapy utilising the genome editing technology CRISPR (NASDAQ:CRSP) | https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease
#FDA #CRISPR #shorts